Ella Therapeutics
Microbiome-based Products for Combination Therapy with Immuno-oncology
Health Tech & Life Sciences
Non Active, Jul 2022 ceased to operate
Company Overview
Snapshot
Founded in May 2019 by Yaron Lemelbaum and Gal Markel, Ella Therapeutics operates with 1–10 employees. The company is in the Pre-Funding stage and ceased operations in July 2022.
Business overview
Ella Therapeutics is a Health Tech & Life Sciences company focused on developing microbiome-based products for combination therapy with immuno-oncology. The company's core technology aims to overcome immunotherapy resistance in cancer patients by altering the gut microbiome through engineered bacteria or a live biotherapeutic product. Ella Therapeutics' platform is designed for major cancer indications, serving the pharmaceutical and life sciences sectors within the broader healthcare market.
Company Intelligence Q&A
- What is Ella Therapeutics' primary focus?
- Ella Therapeutics focuses on developing microbiome-based products for combination therapy with immuno-oncology, aiming to overcome immunotherapy resistance in cancer patients.
- When was Ella Therapeutics founded?
- Ella Therapeutics was founded in May 2019.
- Who are the founders of Ella Therapeutics?
- Ella Therapeutics was founded by Yaron Lemelbaum and Gal Markel.
- What is the status of Ella Therapeutics?
- Ella Therapeutics is currently non-active and ceased to operate in July 2022.
- What is Ella Therapeutics' core technology?
- Ella Therapeutics' core technology aims to overcome immunotherapy resistance in cancer patients by altering the gut microbiome through engineered bacteria or a live biotherapeutic product.